Back

Age- and disease severity-associated changes in the nasopharyngeal microbiota of COVID-19 patients

Perez-Sanz, F.; Tyrkalska, S. D.; Alvarez-Santacruz, C.; Moreno-Docon, A.; Mulero, V.; Cayuela, M. L.; Candel, S.

2023-12-22 respiratory medicine
10.1101/2023.12.20.23300278
Show abstract

Dysbiosis has been linked to the pathogenesis of multiple diseases. Although dozens of publications have associated changes in the nasopharyngeal microbiota to patients susceptibility to COVID-19, results from these studies are highly variable and contradictory in many cases. Addressing the limitations in previous research responsible for that variability, this study uses 16S rRNA gene sequencing to analyse the nasopharyngeal microbiota of 395 subjects, 117 uninfected controls and 278 COVID-19 patients, of different age groups that cover the entire lifespan and across varying disease severities. Importantly, our results reveal that bacterial diversity decreases progressively throughout life but only in severely ill COVID-19 patients, in whose nasopharynx, moreover, the opportunistic pathogen bacterial genera Staphylococcus, Corynebacterium, Streptococcus, Prevotella, Acinetobacter, and Pseudomonas are overrepresented. Notably, Scardovia wiggsiae appears only in severe COVID-19 patients over 60 years of age, suggesting a potential utility of this bacterial species as a COVID-19 severity biomarker in the elderly, who are the most susceptible individuals to suffer from serious forms of the disease and the age group that presents more differences in comparison with the other age groups according to the majority of the parameters analysed in this study. Our results provide valuable insights into age-associated dynamics within nasopharyngeal microbiota during severe COVID-19, offering potential avenues for further exploration and therapeutic interventions.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Respiratory Research
based on 10 papers
Top 0.1%
12.7%
2
Scientific Reports
based on 701 papers
Top 11%
11.3%
3
iScience
based on 74 papers
Top 0.1%
7.7%
4
European Respiratory Journal
based on 44 papers
Top 1%
5.4%
5
ERJ Open Research
based on 36 papers
Top 0.9%
4.6%
6
PLOS ONE
based on 1737 papers
Top 72%
4.6%
7
Journal of Allergy and Clinical Immunology
based on 15 papers
Top 0.5%
2.8%
8
Frontiers in Immunology
based on 140 papers
Top 3%
2.5%
50% of probability mass above
9
Journal of Cystic Fibrosis
based on 10 papers
Top 0.3%
2.5%
10
Genomics, Proteomics & Bioinformatics
based on 10 papers
Top 0.8%
2.3%
11
Clinical and Translational Medicine
based on 11 papers
Top 0.3%
2.3%
12
Frontiers in Medicine
based on 99 papers
Top 8%
2.3%
13
American Journal of Respiratory and Critical Care Medicine
based on 23 papers
Top 0.9%
1.8%
14
Journal of Medical Virology
based on 95 papers
Top 5%
1.8%
15
Cells
based on 14 papers
Top 0.7%
1.6%
16
Environmental Research
based on 36 papers
Top 2%
1.6%
17
BMJ Open Respiratory Research
based on 32 papers
Top 2%
1.3%
18
Frontiers in Microbiology
based on 36 papers
Top 2%
1.3%
19
Proceedings of the National Academy of Sciences
based on 100 papers
Top 9%
1.3%
20
EMBO Molecular Medicine
based on 15 papers
Top 1%
1.3%
21
Frontiers in Pediatrics
based on 24 papers
Top 2%
1.2%
22
mSystems
based on 16 papers
Top 2%
1.2%
23
Thorax
based on 29 papers
Top 2%
1.2%
24
Frontiers in Pharmacology
based on 27 papers
Top 4%
0.8%
25
Allergy
based on 13 papers
Top 1%
0.8%
26
Communications Biology
based on 36 papers
Top 4%
0.8%
27
Viruses
based on 79 papers
Top 6%
0.8%
28
Clinical Immunology
based on 12 papers
Top 2%
0.7%
29
The Lancet Microbe
based on 33 papers
Top 4%
0.7%
30
Nature Genetics
based on 72 papers
Top 9%
0.7%